Komboglyze 2.5mg-850mg Tablets * Pharmacy Only: Prescription
Company:
AstraZeneca Pharmaceuticals (Ireland) DACStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
What is a Patient Information Leaflet and why is it useful?
A Patient Information Leaflet (PIL) is the leaflet for patients containing information on taking a medicine, that is included with the medicine packaging. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). Changes to the PIL after your medicine was packed may mean that the version on medicines.ie may differ from the version found with your medicine. You can compare the “Leaflet prepared or revised date” towards the end of the leaflet in the pack with the version that is on the website to find out if there have been any changes to the information since your medicine was packed.
20230516 Package Leaflet IE MT Komboglyze 2
Last updated: 22/05/23
Product Notice
Discontinued Strength Notice
Supply of Komboglyze 2.5mg-850mg Film-Coated Tablets to the Irish market will be discontinued by September 2024.